Announcements Trials
Browse Landscape

Phase

Phase NA 13Phase 1 12Phase 2 10Phase 3 8Phase 1/2 4Phase 4 2Phase EARLY_PHASE1 1

Status

Unknown 11Completed 9Recruiting 3Withdrawn 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 10Neoplasms 9Polycystic Ovary Syndrome 8Infertility 5Liver Neoplasms 4Pain, Postoperative 3Neoplasm Metastasis 3Multiple Myeloma 3Lung Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Recurrence 2Pulmonary Embolism 2Prostatic Neoplasms 2Pleural Effusion 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroma, Acoustic 2Melanoma 2Lymphoma, Follicular 2Leiomyoma 2Inflammation 2Febrile Neutropenia 2Colorectal Neoplasms 2Bites and Stings 2Anovulation 2Vomiting 1Venous Thrombosis 1Venous Thromboembolism 1

Interventions

5-aminolevulinic acid hexyl ester 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Urinary Bladder Neoplasms × Clear all
NCT06390111 2024-11-22

ABLE-42

Ferring Pharmaceuticals

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

NCT00785694 2015-04-24

Recurrence of Bladder Cancer After Transurethral Resection With Hexvix

GE Healthcare

Phase 4 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡